PIPAC
Witness how pressurized aerosol chemotherapy is transforming the treatment of peritoneal cancer
PIPAC
The Future of Precision Oncology
Pressurized Intraperitoneal Aerosol Chemotherapy represents a paradigm shift in treating peritoneal carcinomatosis, combining minimally invasive surgery with targeted drug delivery.
Treats cancers that have spread to the abdominal lining
Lower chemotherapy dose than systemic treatment
Minimal systemic side effects
Can be repeated multiple times
The Medical Challenge
Why Traditional Methods Fall Short
Peritoneal carcinomatosis has long been considered a terminal diagnosis. Traditional chemotherapy struggles with the peritoneum's unique anatomy and physiology.
Poor drug penetration into peritoneal tumors
High systemic toxicity limits effective dosing
Uneven drug distribution in the abdominal cavity
Limited options for recurrent disease
Minimally Invasive Access
Laparoscopic Precision
Using advanced laparoscopic techniques, we create a sealed therapeutic environment within the abdomen, allowing precise control over drug delivery.
Two small incisions (5-12mm) for trocar placement
CO2 insufflation creates therapeutic space
Specialized nebulizer for drug aerosolization
Real-time pressure monitoring ensures safety
Aerosol Technology
The Power of Pressurized Delivery
Chemotherapy is transformed into a therapeutic aerosol with optimal particle size, ensuring deep tissue penetration and uniform distribution.
Particle size optimized at 1-5 micrometers
12 mmHg pressure drives deep penetration
360-degree coverage of peritoneal surfaces
30-minute exposure time maximizes efficacy
Therapeutic Impact
Measurable Results
PIPAC delivers concentrated chemotherapy directly to tumor sites while preserving quality of life, offering hope where traditional treatments have failed.
Higher local drug concentration at the tumor surface
Aims to reduce tumor burden in the peritoneum
Preserved organ function and mobility
Potential bridge to curative surgery